QuTEM Receives GMP Certificates and Manufacturing Permits for Transmission Electron Microscopy Laboratory from the Swedish Medical Products Agency

May 17, 2024 2:00 AM

QuTEM AB (formerly Vironova BioAnalytics AB), a leading provider of transmission electron microscopy (TEM) services, proudly announces the receipt of GMP (Good Manufacturing Practice) Certificates and Manufacturing Permits for Independent Quality Control Laboratories issued by the Swedish Medical Products Agency (Läkemedelsverket). QuTEM is thereby authorized to perform critical quality control analysis essential for the release of medicines to...

Read more

AppYea Chairman Bary Molchadsky Demonstrates Confidence by Converting Debt to Warrants with a Strike Price Set at a 250% Premium to Current Market Price of the Company’s Common Stock

May 16, 2024 3:30 PM

NEW YORK, NY / ACCESSWIRE / May 16, 2024 / AppYea Inc. (OTCQB:APYP), developer of an innovative wearable monitoring solution to monitor and treat sleep apnea and snoring, today announced the conversion of the majority of debt owed to its Chairman, Boris (Bary) Molchadsky, who converted approximately $140,000 of debt into AppYea warrants with a strike price of $0.07 per share, reflecting a premium of more than 250% over the current market price...

Read more

Adolore BioTherapeutics Announces Publication Demonstrating Carbonic Anhydrase-8 Gene Therapy (rdHSV-CA8) Decreased Pain-Sensing Neuronal Excitability by Activating Kv7 Voltage-Gated Potassium Channels

May 16, 2024 10:00 AM

Findings highlight the advantages of Adolore's approach for the delivery of proprietary gene therapy directly to specialized pain-sensing peripheral nerves (nociceptors) that mediate profound analgesia with the potential to address the great unmet need for non-opioid chronic pain therapiesData further supports the clinical-translational value of Adolore's proprietary non-opioid analgesics for treating chronic non-cancer painCompany continuing...

Read more

Historical Regulatory Filing Deficiences Continue to Stifle Psycheceutical Biosciences

May 16, 2024 9:00 AM

MIAMI, FL / ACCESSWIRE / May 16, 2024 / Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC PINK:BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of neurological treatments, announces the Company's continued inability to undertake certain corporate actions (name and symbol change, M&A, Reverse Split etc.) due to uncorrectable regulatory filing deficiencies from over a...

Read more

BioInvent to Present Additional Promising Phase 1/2a Data at EHA 2024 for BI-1206 with rituximab in NHL

May 14, 2024 10:25 AM

First data for the SC arm: 1 complete response (CR), 2 partial response (PR), 1 stable disease (SD) out of 4 evaluable patients.Further updates from the IV arm; a fifth CR has been observed, adding to a total of 5 CR, 1 PR and 6 SD out of 17 evaluable patients.Data to be presented at the European Hematology Association, June 13-16, 2024.BI-1206 is developed to re-establish the clinical effect of existing cancer treatments such as rituximab and...

Read more

Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe

May 14, 2024 9:15 AM

Lemonaid Health will offer customers more affordable access to branded ED medication STENDRA that may be taken as early as ~15 minutes prior to sexual activity (100mg and 200mg strengths only) [1]Please see Important Safety Information and study design belowNEW YORK, NY / ACCESSWIRE / May 14, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug...

Read more

Vicore Expands and Strengthens its Board of Directors

May 14, 2024 2:20 AM

STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann...

Read more

Ensysce Biosciences Reports First Quarter 2024 Financial Results

May 13, 2024 8:00 AM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today reported financial and operational results for the first quarter ended March 31, 2024.Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "In the first quarter of 2024, we continued to accelerate the...

Read more

Asia Green Biotechnology Corp. Announces Extension of Management Cease Trade Order

May 10, 2024 5:55 PM

[NOT FOR DISTRIBUTION TO U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES]CALGARY, AB / ACCESSWIRE / May 10, 2024 / Asia Green Biotechnology Corp. ("Asia Green" or the "Company") (CSE:ASIA) announces that, further to its news releases dated April 17, 2024, April 26, 2024, and May 8, 2024, the Management Cease Trade Order ("MCTO") issued by the Alberta Securities Commission ("ASC") on May 08, 2024, remains in effect.The MCTO prohibits the...

Read more

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

May 10, 2024 4:15 PM

TORONTO, ON / ACCESSWIRE / May 10, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2024 and provided an update on its business.During the quarter, the company expanded site selection activities for a Phase 3 study of its ARDS (Acute Respiratory...

Read more

Vibrant Wellness Announces UK Expansion, Elevating Personalized Health With Advanced Lab Technology

May 10, 2024 3:30 PM

This expansion marks a significant step towards advancing access to personalized care and longevity worldwide.SANTA CLARA, CA / ACCESSWIRE / May 10, 2024 / Vibrant Wellness, a CLIA-certified and CAP-accredited biotechnology company based in Santa Clara, CA, proudly announced their expansion in the UK.Vibrant is known for their extensive selection of specialty precision lab testing. The company combines biotechnology, innovative software...

Read more

Flightpath Biosciences Begins Human Clinical Testing of the World’s First Narrow-Spectrum Antibiotic Targeting Lyme Disease

May 10, 2024 10:00 AM

DETROIT, MI / ACCESSWIRE / May 10, 2024 / Flightpath Biosciences Inc., a clinical-stage life sciences company developing therapeutics to treat infectious diseases, announced today that the first healthy volunteer participants have been dosed in its Phase I clinical trial of FP-100 (hygromycin A), an orally-available, narrow-spectrum antimicrobial drug candidate. The single center, prospective, randomized, double-blind, placebo-controlled study...

Read more

Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

May 10, 2024 8:30 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the first quarter of 2024 and provided a business update."We have initiated several preclinical studies on the influence of DNase in combination with standard treatment paradigms such as chemotherapy or immune...

Read more

Ondine Biomedical Inc Announces ECDC Report Shows Rising HAIs and Antibiotic Use

May 10, 2024 2:00 AM

Non-regulatory announcementECDC report shows HAIs are increasing antibiotic useA third of microorganisms causing HAIs (healthcare-associated infections) were found to be resistant to antibiotics, leaving doctors with fewer effective treatment options for patientsVANCOUVER, BC / ACCESSWIRE / May 10, 2024 / Ondine Biomedical (LON:OBI): A recent report from the European Centre for Disease Prevention and Control (ECDC) helps underscore the need for...

Read more

Renova Therapeutics Announces Strategic Focus and Roadmap Prioritization for Its Gene Therapies to Treat Heart Failure and Type 2 Diabetes Mellitus

May 8, 2024 9:00 PM

Renova Has Prioritized Two Primary Regulatory Pathways Where It Is Poised to Launch Pivotal Human Trials for Its Promising Gene Therapies to Treat Heart Failure and Type 2 Diabetes MellitusCARLSBAD, CA / ACCESSWIRE / May 8, 2024 / Renova Therapeutics, a biotechnology company developing gene therapy-based treatments for cardiovascular and metabolic diseases, announced today that it has focused its development and commercialization efforts for its...

Read more

enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024 4:15 PM

- Ended the quarter with $42.9 million cash and investments on hand sufficient to fund current operations, including multiple value driving milestones, through the end of 2025- Positive 11-month topline efficacy data presented at the 46th Annual Charing Cross Symposium- Company on track to file PMA Application seeking VenoValve® FDA approval in Q4 2024IRVINE, CA / ACCESSWIRE / May 8, 2024 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or...

Read more

Introducing Cannovation Clinical Research Partners, LLC: Pioneering the Future of BioPharmaceutical Cannabinoid-Based Therapeutics

May 8, 2024 6:00 AM

Cannovation Clinical Research Partners, a pioneering Cannabis-Based Clinical Research Organization for Drug and Product Development, is proudly announcing its official launch, marking a significant milestone in pharmaceutical and biotech innovation. Founded by esteemed pharmaceutical and biotech executive Lisa Rich-Milan, alongside seasoned cannabis industry leader Michael Zaccaria, Cannovation aims to spearhead a revolution in medicine through...

Read more

NovAccess Global Advisory on Annual Meeting of Shareholders

May 7, 2024 11:25 AM

NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the postponement of its Annual Meeting of Shareholder which was previously scheduled to be held in May 2024. The Company expects to reschedule the annual meeting shortly.The Company previously announced that it would be hosting a virtual annual meeting of shareholders on May 6th, 2024 for shareholders of record as...

Read more

Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)

May 7, 2024 9:25 AM

STOCKHOLM, SE / ACCESSWIRE / May 7, 2024 / Vicore Pharma Holding (STO:VICO)The following resolutions were passed at the annual general meeting (the "AGM") of Vicore Pharma Holding AB (publ) on 7 May 2024.Adoption of income statement and balance sheet for the financial year 2023 and discharge from liabilityThe AGM resolved to adopt the income statement and the consolidated income statement for the financial year 2023 as well as the balance sheet...

Read more

Form Bio Announces In Silico Assays, Enabling Gene Therapy Companies and Their Research Partners to Accelerate the Vector Discovery & Development Process

May 7, 2024 8:00 AM

New Capabilities Empower Gene Therapy Developers to Explore a Broader Range of Vector Designs and Rapidly Identify Candidates Best Poised for IND Speed and SuccessSAN FRANCISCO, CA / ACCESSWIRE / May 7, 2024 / Form Bio, the provider of advanced computational life sciences technology, today announced the launch of In Silico Assays, a new set of capabilities for computationally screening vector designs prior to in vitro screening. In Silico Assays...

Read more